Abstract
Corynebacterium striatum is an emerging multidrug-resistant bacteria. We retrospectively identified 179 isolates in a clinical database. Clinical relevance, in vitro susceptibility, and length of parenteral antimicrobial drug use were obtained from patient records. For patients with hardware- or device-associated infections, those with C. striatum infections were matched with patients infected with coagulase-negative staphylococci for case–control analysis. A total of 87 (71%) of 121 isolates were resistant to all oral antimicrobial drugs tested, including penicillin, tetracycline, clindamycin, erythromycin, and ciprofloxacin. When isolated from hardware or devices, C. striatum was pathogenic in 38 (87%) of 44 cases. Patients with hardware-associated C. striatum infections received parenteral antimicrobial drugs longer than patients with hardware-associated coagulase-negative staphylococci infections (mean ± SD 69 ± 5 days vs. 25 ± 4 days; p<0.001). C. striatum commonly shows resistance to antimicrobial drugs with oral bioavailability and is associated with increased use of parenteral antimicrobial drugs.
Highlights
This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases
We identified 179 immunocompetent adult patients infected with C. striatum isolated from clinical specimens
Consistent with previous reports that C. striatum is a colonizer of the skin and mucous membranes, isolates were frequently reported in sputum and skin samples (65/179) (Figure 1)
Summary
This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. In vitro susceptibility, and length of parenteral antimicrobial drug use were obtained from patient records. Early reports indicated that C. striatum isolates were frequently susceptible to many antimicrobial drugs, including β-lactams, tetracycline, and fluoroquinolones [8,9,10,11], more recent studies have demonstrated increasing multidrug resistance [12,13,14,15,16,17].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
